$1.67 Billion is the total value of Camber Capital Management LP's 29 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 55.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $148,154,000 | +56.6% | 1,650,000 | +88.6% | 8.85% | +83.7% |
| CHNG | New | CHANGE HEALTHCARE INC | $129,870,000 | – | 13,000,000 | +100.0% | 7.76% | – |
| MYL | Sell | MYLAN N V | $116,223,000 | -33.9% | 7,795,000 | -10.9% | 6.94% | -22.5% |
| GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $113,670,000 | – | 3,000,000 | +100.0% | 6.79% | – |
| UHS | Buy | UNIVERSAL HLTH SVCS INCcl b | $111,465,000 | +55.4% | 1,125,000 | +125.0% | 6.66% | +82.4% |
| PRGO | Buy | PERRIGO CO PLC | $96,180,000 | +9.5% | 2,000,000 | +17.6% | 5.74% | +28.5% |
| ABBV | New | ABBVIE INC | $91,428,000 | – | 1,200,000 | +100.0% | 5.46% | – |
| ALKS | Buy | ALKERMES PLC | $87,241,000 | +3.7% | 6,050,000 | +46.7% | 5.21% | +21.7% |
| VTR | Buy | VENTAS INC | $87,100,000 | +101.1% | 3,250,000 | +333.3% | 5.20% | +136.0% |
| HCA | Buy | HCA HEALTHCARE INC | $76,373,000 | +29.2% | 850,000 | +112.5% | 4.56% | +51.6% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $70,920,000 | -8.4% | 725,000 | +20.8% | 4.24% | +7.5% |
| BIIB | Sell | BIOGEN INC | $63,276,000 | -39.1% | 200,000 | -42.9% | 3.78% | -28.5% |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $60,439,000 | -34.5% | 536,710 | -19.0% | 3.61% | -23.1% |
| MNTA | Sell | MOMENTA PHARMACEUTICALS INC | $54,400,000 | -15.2% | 2,000,000 | -38.5% | 3.25% | -0.5% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $53,550,000 | -33.8% | 3,000,000 | -20.0% | 3.20% | -22.4% |
| BKD | Buy | BROOKDALE SR LIVING INC | $53,040,000 | -41.6% | 17,000,000 | +36.0% | 3.17% | -31.5% |
| THC | Buy | TENET HEALTHCARE CORP | $50,400,000 | -47.0% | 3,500,000 | +40.0% | 3.01% | -37.8% |
| MYGN | Buy | MYRIAD GENETICS INC | $33,629,000 | +23.5% | 2,350,000 | +135.0% | 2.01% | +44.9% |
| COLL | New | COLLEGIUM PHARMACEUTICAL INC | $32,660,000 | – | 2,000,000 | +100.0% | 1.95% | – |
| AMAG | AMAG PHARMACEUTICALS INC | $27,130,000 | -49.2% | 4,390,000 | 0.0% | 1.62% | -40.4% | |
| INCY | New | INCYTE CORP | $26,396,000 | – | 360,457 | +100.0% | 1.58% | – |
| AVRO | Buy | AVROBIO INC | $21,006,000 | +73.9% | 1,350,000 | +125.0% | 1.25% | +103.9% |
| TBIO | Buy | TRANSLATE BIO INC | $17,597,000 | +44.1% | 1,765,000 | +17.7% | 1.05% | +69.2% |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $16,458,000 | – | 1,950,000 | +100.0% | 0.98% | – |
| ATRA | Sell | ATARA BIOTHERAPEUTICS INC | $12,584,000 | -74.1% | 1,478,753 | -49.9% | 0.75% | -69.6% |
| GLYC | GLYCOMIMETICS INC | $7,980,000 | -56.9% | 3,500,000 | 0.0% | 0.48% | -49.4% | |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $7,650,000 | – | 2,500,000 | +100.0% | 0.46% | – |
| STRO | SUTRO BIOPHARMA INC | $6,120,000 | -7.3% | 600,000 | 0.0% | 0.36% | +8.6% | |
| NUVA | New | NUVASIVE INC | $1,704,000 | – | 33,630 | +100.0% | 0.10% | – |
| TEVA | Exit | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $0 | – | -2,000,000 | -100.0% | -1.00% | – |
| MD | Exit | MEDNAX INC | $0 | – | -790,000 | -100.0% | -1.12% | – |
| MYL | Exit | MYLAN N Vcall | $0 | – | -1,600,000 | -100.0% | -1.64% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -730,000 | -100.0% | -2.95% | – |
| THOR | Exit | SYNTHORX INC | $0 | – | -1,000,000 | -100.0% | -3.56% | – |
| DVA | Exit | DAVITA INC | $0 | – | -1,000,000 | -100.0% | -3.82% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -1,500,000 | -100.0% | -4.96% | – |
| AGN | Exit | ALLERGAN PLC | $0 | – | -1,000,000 | -100.0% | -9.73% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.